|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present work we combined functional and spectroscopic magnetic resonance technologies, such as in vivo diffusion-weighted MRI and <sup>1</sup> H MRS, with ex vivo high resolution MRS (HR-MRS) metabolomic analyses, with the aim of identifying new pharmacodynamic markers of Trab effectiveness on well characterized, highly aggressive human SKOV3.ip (a HER2-enriched cell variant derived from SKOV3 cells) EOC xenografts.
|
30375088 |
2019 |
|
Epithelial ovarian cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SYD985 and T-DM1 induced similar ADCC in the presence of peripheral blood lymphocytes (PBL) against EOC cell lines with differential HER2/neu expression.
|
28473206 |
2017 |
|
Epithelial ovarian cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overall, these findings support the view that PC-PLC inhibition may represent an effective means to target the tumorigenic effects of HER2 overexpression in EOC and that <i>in vivo</i> MR approaches can efficiently monitor its effects.
|
28903399 |
2017 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Goals of this study were: i) to define a possible association between Estrogen Receptor (ER), Progesterone Receptor (PR), Androgen Receptor (AR),human EGF receptor 2 (HER2) and brain progression in EOC patients, and ii) to identify differences in ER, PR, AR and HER2 protein expression from primary EOC and its matched resected brain metastasis.
|
28467804 |
2017 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
T, P, T+P, and T-DM1 were similarly effective in inducing strong ADCC against primary EOC cell lines expressing 3+ HER2/neu.
|
28705408 |
2017 |
|
Epithelial ovarian cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PubMed and Embase were searched for studies that reported HER-2/neu expression and survival in patients with EOC.
|
29088888 |
2017 |
|
Epithelial ovarian cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Future prospective cohorts with larger samples are needed to verify the prognostic value of Her-2 expression in EOC.
|
26045112 |
2016 |
|
Epithelial ovarian cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The IHC results showed that protein of KIF2A and HER2-neu was overexpressed in EOC tissues compared with normal ovary or fallopian tube tissues, and KIF2A expression level was significantly associated with lymph nodes, metastasis, ascites cells, and FIGO stage.
|
26937910 |
2016 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Forty-nine tissue microarray (TMA) samples of mucinous EOC from Asian women were analyzed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) tests using ToGA trial HER2 scoring methods.
|
26566289 |
2015 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, there is currently no standardization of HER2 scoring criteria in mucinous EOC.
|
25501060 |
2014 |
|
Epithelial ovarian cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a meta-analysis.
|
23873100 |
2014 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The prevalence of HER2 positivity in Asian mucinous EOC was 9 of 49 Asian women (18.37%).
|
25133707 |
2014 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We here investigated the effects of a cytostatic cisplatin (CDDP) treatment on (1)H MRS and MRI of HER2-overexpressing epithelial ovarian cancer (EOC) cells and in vivo xenografts.
|
24335926 |
2014 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tests for the HER2 gene copies per tumor cell either before or after correction of chromosome-17 can be applied as a potentially valuable tool to analyze the HER2 status in mucinous EOC.
|
24656091 |
2014 |
|
Epithelial ovarian cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We conducted a phase II trial to evaluate the activity and tolerability of lapatinib in patients with recurrent or persistent epithelial ovarian cancer (EOC) and to explore the clinical value of expression levels of epidermal growth factor receptors (EGFR), phosphorylated EGFR, HER-2/neu, and Ki-67, and the presence of EGFR mutations.
|
22037316 |
2012 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization.
|
21623202 |
2011 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrated that both chromosome-17 corrected and uncorrected HER2 gene copies correlated significantly with HER2 IHC result categories; and tests for the HER2 gene copies per tumor cell either before or after correction for chromosome-17 can be applied as a potentially valuable tool in analyzing the HER2 status in EOC.
|
21046136 |
2011 |
|
Epithelial ovarian cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HER2 protein overexpression correlated significantly with HER2 gene amplification in EOC (P = 0.027).
|
21347793 |
2011 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amplifications and overexpression of various EGFR family members, including EGFR, Her2, and ErbB3, have been reported in epithelial ovarian cancer.
|
21364581 |
2011 |
|
Epithelial ovarian cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Pertuzumab is a humanized monoclonal antibody that inhibits human epidermal growth factor receptor 2 (HER2) heterodimerization and has single-agent activity in recurrent epithelial ovarian cancer.
|
19901115 |
2010 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
ERBB2 amplification, defined as >2 copies of ERBB2/CEP17, was a rare event in EOC with 7% (9/133) of women exhibiting between 2.2 and 33.7 copies of ERBB2/CEP17, and was not associated with patient age, race, GOG performance status, stage, cell type, grade, measurable disease status, volume of ascites, tumor response or disease status post-chemotherapy.
|
19272639 |
2009 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We determined the tumour mutation status of the entire tyrosine kinase (TK) domain of the EGFR and HER2-neu genes in a cohort of 52 patients with invasive epithelial ovarian cancer as well as the gene copy number and protein expression of both genes in 31 of these patients by DGGE and direct sequecing, immunohistochemistry and Fluorescent in Situ Hybridisation (FISH).
|
18182111 |
2008 |
|
Epithelial ovarian cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HER2/neu is up-regulated more often in CCC than in other histologic types of epithelial ovarian cancer.
|
17218636 |
2007 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunostaining was performed for COX2/HER2 together with FISH analysis for HER2 gene amplification in 160 patients with EOC, FIGO stages IIB-IV.Follow-up was more than 10 years.
|
17309668 |
2007 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The invasion and metastasis mechanism of epithelial ovarian cancer is a very complex process in which many important genes like nm23, c-erbB-2, as well as other unknown genes or expressed sequence tags were involved.
|
16445634 |
2006 |